Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	268 people with preliminary ACR criteria for gout and serum uric acid 8.0 mg/dL or higher Data from 1 RCT	Proportion of people with serious adverse effects at 28 weeks 5/134 (4%) with febuxostat 240 mg 2/134 (2%) with placebo	RR 2.50 95% CI 0.49 to 12.66		Not significant
Systematic review	268 people with preliminary ACR criteria for gout and serum uric acid 8.0 mg/dL or higher Data from 1 RCT	Proportion of people with skin reaction at 28 weeks 6/134 (4.5%) with febuxostat 240 mg 7/134 (5.2%) with placebo	RR 0.86 95% CI 0.30 to 2.48		Not significant